Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.
Institutional and Insider Ownership
98.6% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Protagonist Therapeutics and AbCellera Biologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Protagonist Therapeutics | 29.40% | 12.03% | 11.23% |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Protagonist Therapeutics | $281.99 million | 31.27 | -$130.15 million | $1.03 | 132.31 |
| AbCellera Biologics | $66.17 million | 57.32 | -$146.41 million | ($0.54) | -22.91 |
Protagonist Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Protagonist Therapeutics and AbCellera Biologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Protagonist Therapeutics | 0 | 1 | 16 | 1 | 3.00 |
| AbCellera Biologics | 1 | 2 | 5 | 2 | 2.80 |
Protagonist Therapeutics currently has a consensus target price of $154.44, indicating a potential upside of 13.32%. AbCellera Biologics has a consensus target price of $13.89, indicating a potential upside of 12.28%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than AbCellera Biologics.
Risk & Volatility
Protagonist Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats AbCellera Biologics on 12 of the 15 factors compared between the two stocks.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
